Daily Stock List
Lenco Mobile, Inc. (LNCM)
Today we are reporting on Lenco Mobile, Inc. (LNCM), here at the QualityStocks Daily Newsletter.
Lenco Mobile, Inc. is an international provider of proprietary mobile messaging and mobile web solutions. In December 2011, iLoop Mobile and Lenco Mobile merged to form a global mobile technology and services firm. In June 2012, the combined companies began the process of rebranding under a unified name, Archer. Lenco Mobile (currently changing their company name to Archer) has their corporate headquarters in Seattle, Washington.
This union of the two companies gives the Company the expertise and technology to support customers in developing and launching large-scale mobile initiatives. They offer distinctive high performance MMS capabilities along with SMS, Mobile Web, Mobile Social Integration, International Services, Carrier Products, and a wide spectrum of vertical specific solutions.
The Company has delivered over two billion MMS messages, hundreds of millions of SMS messages, and five billion mobile Web page views, worldwide. Archer combines the best of Lenco Mobile's international operations and rich media platform with iLoop Mobile's marketing technology and leadership in the U.S. They've launched tens of thousands of global initiatives for Fortune 500 companies, brands, retailers, agencies, as well as public institutions.
Archer can reach 6 billion people in the most personal way possible, which is through their mobile phones. The Company can integrate fast and easily with their customers' systems and related technology. The open architecture of the Archer Mobile Platform offers APIs that support integration with CRM systems, reporting, content-management systems, databases, message aggregators, and other third-party applications.
Recently, Lenco Mobile (Archer) announced results for the quarter ended September 30, 2012. The Company reported revenues of $4.2 million. This represents an increase of 51 percent from the third quarter of 2011. Gross profit increased 37 percent year-over-year to $2.4 million.
Operating expenses increased 11 percent year-over-year to $4.6 million. As of September 30, 2012, Lenco Mobile had cash and cash-equivalents of approximately $0.2 million and a net working capital deficit of $11.1 million. Cash used in operations during the nine months ended September 30, 2012 totaled $6.6 million.
Lenco Mobile, Inc. (LNCM), closed Thursday's session at $0.025, down 37.50%, on 211,635 volume with 9 trades. The average volume for the last 60 days is 37,096 and the stock's 52-week low/high is $0.025/$0.38.
BioNitrogen Corp. (BION)
Wall Street Stallions reported last week on BioNitrogen Corp. (BION), FeedBlitz, SmallCapVoice, Top Secret IPO, PowerPennyStocks, Hidden Values Alert, Bold Stocks, StockGuru, Wyatt Investment Research did earlier, and we are highlighting the Company, here at the QualityStocks Daily Newsletter.
BioNitrogen Corp. focuses on building fully operational, turnkey manufacturing facilities in the global marketplace to produce urea. Urea is a white, crystalline, solid containing 46 percent nitrogen. Its principal use is in the agricultural industry as a crop fertilizer. The Company is utilizing their patent-pending technologies to transform residual agricultural waste and other biomass materials into high-quality bulk urea for sale to agricultural wholesalers and retailers. BioNitrogen has their corporate headquarters in Doral, Florida.
BioNitrogen's mission is to provide safe, cost effective green solutions that are economically beneficial in locations where biomass is produced and urea is consumed. The Company's facilities are modular in design and substantially smaller than traditional urea production plants. Their facilities will be able to manufacture 15 tons of urea fertilizer per hour for total annual production of approximately 124,200 tons per plant. BioNitrogen's products will help improve crop yields and will contribute to an increased global food supply.
The Company's specialty is the production of bulk urea for sale as fertilizer. Nitrogen is one of the major nutrients, along with phosphorus and potassium. In recent years, demand for urea by the commercial and industrial sectors has been increasing steadily. BioNitrogen also produces urea for these markets.
Pertaining to Industrial uses, Urea is used to produce animal feed, some types of plastics, glues, toilet bowl cleaners, dishwasher detergents, hair coloring products, pesticides and fungicides. Urea is used in pharmaceuticals (e.g. barbiturates and diuretics) and as a component in dermatological products that re-hydrate the skin. It is also a main ingredient of hair removal products, a browning agent in factory-made pretzels, a cloud seeding agent, and a flameproofing agent.
Last month, BioNitrogen announced that the Hardee County Industrial Development Authority (IDA) allocated $2 million dollars in grants to BioNitrogen's Florida Plant subsidiary for reimbursable expenses incurred during the construction of the Hardee County plant. One million of the total $2 million was transferred from the Hardee County Economic Development Authority (EDA) to the IDA. The EDA Board unanimously approved the transfer. The funds will be used to cover expenses related to the rail spur, construction and engineering of the initial plant. The intention is that construction on the site will begin in early 2013. The proposed plant will be able to produce 15 tons of urea fertilizer hourly, totaling 360 short tons daily or 124,200 tons annually.
BioNitrogen Corp. (BION), closed Thursday's trading session at $0.059, up 14.12%, on 751,812 volume with 46 trades. The average volume for the last 60 days is 347,519 and the stock's 52-week low/high is $0.003/$1.75.
Global Gaming Network, Inc. (GBGM)
Global Investment Alert, Penny Stock Rumble, FeedBlitz, Pumps and Dumps, PennyStockCrowd, and Penny Stocks Profile reported recently on Global Gaming Network, Inc. (GBGM), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Listed on the OTC Pink Current Information, Global Gaming Network, Inc. is a developer, distributor and aggregator of digital entertainment and sports information for online and mobile platforms. The Company owns and operates SportsAlert.com, the leading independent mobile sports information service in the U.S. and Canada. They also own and operate AmpedFantasy.com, a daily and weekly Fantasy Sports operation that offers their users contests for cash and prizes. Global Gaming Network is based in Los Angeles, California.
The Company's SportsAlert.com is a free, advertiser supported text message information service. It provides real time sports scores and updates to subscribers' mobile telephones. Global Gaming Network is actively pursuing additional acquisitions and affiliations in compatible fields.
SportsAlert.com sends sports scores to cell phones or email for a host of leagues. These include the NBA, NHL, MLB, NFL, NCAA Football, NCAA Basketball, and the World Cup. SportsAlert.com's partners include yellowbook and the Power Up Motorsports Channel.
Last week, Global Gaming Network announced that the Company made major improvements to their Amped Fantasy website www.AmpedFantasy.com. Amped Fantasy allows users to legally wager on players that participate in domestic sporting events. The Company believes that the website's additions should allow Amped Fantasy to increase their user base significantly during the remainder of the NFL season. This includes the playoff games and Super Bowl 2013.
Mr. Stephen Kern, President of Global Gaming Network, said, "We're pleased to offer our expanding and loyal user base a much improved Amped Fantasy website, with new features, contests, special promotions and social networking tie-ins. Users will now be able to pick and store their favorite players for contests, play 'freeroll' contests for cash with no entry fee, win a free trip to Baja Mexico and receive gift certificates from well known outlets like Restaurant.com and 1-800-flowers .com. Users can now directly access the Amped Fantasy blog for valuable information on player performance, injuries, etc., and post their entered contests on Facebook and Twitter."
Global Gaming Network, Inc. (GBGM), closed Thursday's trading session at $0.0055, down 20.29%, on 323,419 volume with 8 trades. The average volume for the last 60 days is 585,114 and the stock's 52-week low/high is $0.003/$0.49.
Golden Agri-Resources Ltd. (GARPF)
We are highlighting Golden Agri-Resources Ltd. (GARPF), here at the QualityStocks Daily Newsletter.
Founded in 1996, Golden Agri-Resources Ltd. is the world's second largest palm oil plantation company. Their goal is to be the fastest-growing and lowest-cost integrated oil palm company in the world. Flambo International Ltd. (an investment company) is Golden Agri-Resources' largest shareholder, having a 49.95 percent stake. In addition, Golden Agri-Resources has a number of subsidiaries, including PT SMART Tbk (listed on the Indonesia Stock Exchange since 1992. Golden Agri-Resources (GAR) - based in Singapore - lists on the OTC Pink Current Information.
GAR has integrated operations focusing on the production of palm-based edible oil and fat. The Company has a total planted area of 459,500 hectares (including smallholders) located in Indonesia, as at September30, 2012. GAR is concentrating on 'sustainable' palm oil production. The Company's size allows them to benefit from economies of scale and to develop best expertise in different areas. These areas include research and development (R&D), plantation management, sourcing of materials, and access to domestic and worldwide markets.
The Company's main activities in Indonesia include the cultivation and harvesting of oil palm trees; the processing of fresh fruit bunch into crude palm oil (CPO) and palm kernel; and refining CPO into value-added products (e.g. cooking oil, margarine and shortening). Furthermore, GAR has integrated operations in China. This includes a deep-sea port, oilseeds crushing plants, production capabilities for refined edible oil products, as well as other food products including noodles. The Company produces more than 2.5 million tonnes of palm products each year.
GAR produces bulk products, such as crude palm oil, palm kernel, palm kernel oil, palm kernel meal, olein, stearin, cocoa butter substitute, and soybean oil and soybean meal. Moreover, the Company also produces a complete spectrum of refined branded products. These products include cooking oil, margarine, butter oil substitute, shortening and fats for end-customers, restaurants, hotels, cafés and industrial markets.
The Company's vertically integrated business activities In Indonesia include seedlings, plantations, extraction, refining, and kernel crushing. They also include marketing, and GAR has their own in-house R&D facilities.
Golden Agri-Resources Ltd. (GARPF), closed Thursday's trading session at $0.545, even for the day. The average volume for the last 60 days is 37,940 and the stock's 52-week low/high is $0.45/$0.63.
JNR Resources, Inc. (JNN.V)
Streetwise Reports reported previously on JNR Resources, Inc. (JNN.V), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
JNR Resources, Inc. is a junior resource company with headquarters in Saskatoon, Saskatchewan. The Company engages in the exploration and development of mineral properties in the provinces of Saskatchewan and Newfoundland. Their primary focus is in the Athabasca Basin, recognized as the most prospective uranium-mining district in the world. JNR also holds an interest in two highly prospective uranium properties in Newfoundland. JNR Resources' shares trade on the TSX Venture Exchange and on the OTC Pink Current Information under the symbol JNRRF.
The Company has a diverse interest in several prospective uranium properties in the Athabasca Basin of northern Saskatchewan. These have been and will continue to be the focal point of their exploration efforts.
JNR Resources uranium projects in the Athabasca Basin are Bell Lake, Black Lake, Crackingstone, Lazy Edward Bay, Moore Lake (Maverick Zone), Newnham Lake, and North Wedge. Projects in the Basin also include Snowbird, South Dufferin, South Cigar, Way Lake, and Yurchison Lake. The 26,550 hectare Bell Lake project is approximately 50 to 75 kilometers northwest of the Rabbit Lake mine and within 5 kilometers of Cameco's La Rocque Lake uranium zone, where intersections of up to 33.9 percent U3O8 over 5.5 meters have been reported.
The Company also has their South Fork Uranium Project in Saskatchewan. The 17,792-hectare South Fork property is in the eastern end of the Cypress Hills area of southwestern Saskatchewan. JNR holds a 50 percent interest in the project. Joint Venture partner, Mega Uranium Ltd., holds the remaining 50 percent and is the project operator.
In Newfoundland, JNR Resources has their 6,450 hectare Rocky Brook property located in the Deer Lake Basin of Western Newfoundland. JNR optioned Rocky Brook from Altius Minerals Corp. in December of 2004. They fulfilled their requirements to earn a 70 percent interest in the property in April of 2009. Since that time, JNR has been funding all exploration activities on a 100 percent basis to increase their ownership position. Consequently, their interest in the Rocky Brook project is currently 73.4 percent. In addition, they have their 105,675 hectare Topsails uranium property located in West Central Newfoundland.
JNR Resources, Inc. (JNN.V), closed Thursday's trading session at $0.075, even for the day, on 676,550 volume. The stock's 52-week low/high is $0.05/$0.22.
Medical Marijuana, Inc. (MJNA)
SmallCapVoice reported yesterday on Medical Marijuana, Inc. (MJNA), OTC Stock Review, Pennybuster, The Green Baron, SmallCapReview, Penny Stock Rumble, SmallCapStockPlays, Greenbackers did recently, and we are highlighting the Company today, here at the QualityStocks Daily Newsletter.
Listed on the OTC Pink Current Information, Medical Marijuana, Inc.'s mission is to be the premier cannabis and hemp industry innovators. The Company is leveraging their team of professionals to source, evaluate, and purchase value-added companies and products. The Company is the first publicly held enterprise vested in the medical marijuana and industrial hemp markets. Based in San Diego, California, Medical Marijuana consists of a varied portfolio of products, services, technology and businesses solely focused on the cannabis and hemp industries.
The Company provides more than 50 proprietary and patented cannabinoid "delivery methods" that are more "socially and medically acceptable" than smoking. Medical Marijuana does not grow, sell or distribute any substances that violate United States Law or the controlled substance act. Products range from patented and proprietary based cannabinoid products, to whole plant or isolated high value extracts specifically manufactured and formulated for the pharmaceutical, nutraceutical, as well as cosmeceutical industries.
The Company's services range from medical clinic management to the capitalization and development of existing industry business and product leaders. Their services include development of cannabinoid based health and wellness products, and the development of medical grade compounds. Medical Marijuana services include the licensing of their proprietary testing, genetics, labeling, and packaging, tracking, and production and standardization methods for the medicinal herb industry.
Medical Marijuana's PhytoSPHERE Systems and their advanced plant growth technologies save greatly on resources necessary for the production of medical grade cannabis. PhytoSPHERE Systems' provides a medical grade end product, extracts and compounds. PhytoSPHERE Systems also includes pre-and-post production tracking, gemplasm references, packaging, and processing, to ensure consistency and genetic purity. PhytoSPHERE Systems is a pharmaceutical grade vertical Bio-Technology Company specializing in the standardization, production and extraction of medicinal cannabinoids.
Medical Marijuana earned net income of approximately $1.19 million on gross revenues of $3.00 million for the quarter ended Sept 30, 2012. This represents a gross revenue increase of 1,500 plus percent quarter-over-quarter when compared to revenue of $198,813 for the quarter ended Sept 30, 2011.
Medical Marijuana, Inc. (MJNA), closed Thursday at $0.11, up 5.16%, on 7,481,266 volume with 532 trades. The average volume for the last 60 days is 7,990,400 and the stock's 52-week low/high is $0.011/$0.37.
MGM Energy Corp. (MGX.TO)
We are highlighting MGM Energy Corp. (MGX.TO), here at the QualityStocks Daily Newsletter.
MGM Energy Corp. is an energy company focusing on the acquisition and development of hydrocarbon resources in the Northwest Territories and the Arctic regions. Currently, the Company is active in two areas. One is the Mackenzie Delta where they own interests in six discoveries. The second is the Colville Lake/Sahtu region of the Central Mackenzie Valley, where they own interests in two discoveries. MGM Energy has their corporate headquarters in Calgary, Alberta. The Company's shares trade on the Toronto Stock Exchange.
The Company's business strategy is to acquire interests in prospective lands and existing discoveries in the Canadian North, and to bring current technology to bear on the exploration of those lands. Their intention is developing projects that will ship hydrocarbons through the Mackenzie Valley pipeline (once built). MGM Energy land holdings include Federal Lands and First Nations Oil and Gas Concessions.
MGM Energy was the successful bidder in the July 6, 2010 land sale concerning the Mackenzie Delta. The Company picked up four licenses on the Mackenzie Delta and one license in the Central Mackenzie Corridor. The four licenses on the Delta cover more than 290,000 hectares of exploration rights. When they are added to the Company's existing exploration lands (Umiak, Burnt Lake, Mallik blocks and Ogruknang), it gives MGM Energy more than 433,000 hectares of land that they can explore.
The Mackenzie Delta sits at the end of the Mackenzie River. There, it enters the Beaufort Sea, approximately 2,200 kilometers northwest of Calgary. MGM Energy has several exploration prospects and leads, some drill ready, on the Mackenzie Delta licenses. They will be further evaluating their portfolio as well as opportunities in the coming months.
In the Central Mackenzie Valley, MGM Energy has a number of assets. As at December 31, 2011, the properties in the area covered approximately 372,000 gross hectares (approximately 343,000 hectares net to MGM Energy).
MGM Energy Corp. (MGX.TO), closed Thursday's trading at $0.19, up 2.70%, on 171,337 volume. The stock's 52-week low/high is $0.13/$0.28.
Panacea Global, Inc. (PANG)
Information Solutions Group reported earlier on Panacea Global, Inc. (PANG), and today we choose to highlight the Company, here at the QualityStocks Daily Newsletter.
Trading on the OTC Bulletin Board, Panacea Global, Inc. is a biotechnology company focusing on the development and commercialization of diagnostic products for the management of cancer. Their lead technology provides an accurate, timely, cost effective and non-invasive early cancer detection test to increase the quality of life of cancer patients and ultimately save lives. Founded in 1999, and a Corporation incorporated under the laws of Nevada, Panacea Global has their headquarters in Richmond Hill, Ontario.
On June 30, 2010, Panacea Global entered into a share exchange agreement with Panacea Global, Inc., a privately held Delaware corporation (Panacea Delaware), and the shareholders of Panacea Delaware whereby they acquired all of the outstanding capital stock of Panacea Delaware from the Panacea Delaware shareholders and Panacea Delaware became the Company's wholly owned subsidiary and their operating business. Through Panacea Delaware, Panacea Global is a biopharmaceutical company that anticipates selling early detection cancer tests via their licensing agreement with Panacea Pharmaceuticals, Inc.
Panacea Global has the exclusive global (excluding the United States) rights to HAAH-based cancer tests. The Company's early cancer detection test detects the presence of the human aspartyl (asparaginyl) β-hydroxylase (HAAH). This is a novel biomarker expressed in malignant cancer cells and detected in patients' blood samples measured using an ELISA assay. In a double blind study of 857 samples, conducted previously by the Company, the test showed 94.7 percent sensitivity, 94.3 percent specificity and an overall accuracy of 94.6 percent.
Panacea Global acquired a Global Diagnostic License (GDL) with rights to sublicense their technology globally, except for the United States of America. The GDL allows the Company to develop, market, and use licensed products related to HAAH based laboratory tests for two patents pending. One is Methods of Diagnosing, Predicting Therapeutic Efficacy and Screening for New Therapeutic Agents for Leukemia – Pending. The other is Methods of Diagnosing Lung Cancer – Pending.
The Company has the worldwide exclusive rights on their present product line. This includes diagnostics for colon, breast, lung, and prostate cancers. Their BC Detect® is a novel blood test for breast cancer diagnostics. CC Detect® is a serum test for colorectal cancer diagnostics. LC Detect® is a serum test for lung cancer diagnostics. PC Detect® is a serum test for prostate cancer diagnostics. All of these products work by measuring serum levels of HAAH.
Panacea Global also has their TK Sense® product. TK Sense® is a useful blood test for patients with chronic myelogenous leukemia (CML) who may begin treatment with or continue treatment with imatinib (Gleevec®). TK Sense® measures the level of HAAH gene expression.
Panacea Global, Inc. (PANG), closed Thursday's trading session at $0.49, up 4.26%, on 15,000 volume with 3 trades. The average volume for the last 60 days is 3,785 and the stock's 52-week low/high is $0.025/$0.95.
VIASPACE, Inc. (VSPC)
The QualityStocks Daily Newsletter would like to spotlight VIASPACE, Inc. (VSPC). Today, VIASPACE, Inc. closed trading at $0.013, up 18.18%, on 4,544,458 volume with 36 trades. The stock’s average daily volume over the past 60 days is 1,733,035, and its 52-week low/high is $0.0013/$0.015.
VIASPACE, Inc. reported on a detailed interview of Board Chairman, Dr. Kevin Schewe, by Juan Costello of the WallStreetReporter last Friday (Nov 30), wherein the subject of recent corporate developments, as well as the company's moves to position for massive shareholder growth in bioenergy, were covered. Dr. Schewe was keen to point out how he dedicated significant time in the front half of the interview to educating newer investors in this audience regarding the company's history and current developments, and how the final two questions, concerning VSPC's outlook and current status, gave him a chance to really put the potential of Giant King Grass for green and clean bioelectricity projects on the map.
VIASPACE, Inc. (VSPC) is focused on growing renewable Giant King™ Grass as a low-carbon fuel for clean electricity generation and environmentally friendly energy pellets, as well as a feedstock for bio-methane production, green cellulosic biofuels, biochemical, and biomaterials. A high-yield, low-cost feedstock, Giant King Grass meets the cost targets of green energy applications while maintaining a carbon neutral profile.
The highest yielding biomass crop in the world, Giant King Grass can grow in a variety of soil conditions and does not compete with food crops. Once Giant King Grass is established, it can be harvested at 3-5 feet tall every 45 to 60 days or at 14 feet tall twice a year. This incredibly high rate of growth provides a continual supply of biomass year-round, enabling strategically located power plants to operate 24 hours a day regardless of the current season.
VIASPACE provides Giant King™ Grass seedlings and technical expertise to qualified projects. The company also plans to serve as a project developer or co-developer for power plant or pellet mill projects, together with local partners that have land and require electricity, heat, pellets, biogas, or biofuels. VIASPACE and its partners are capable of delivering an integrated Giant King Grass plantation and biomass power plant project in just 24 months.
The excellent energy characteristics of Giant King Grass and its ability to be harvested multiple times each year enable and energy output yield that is much higher than other crops . This superior feedstock offers material productivity benefits at remarkable costs for energy production, biofuels, and biomaterials. Giant King Grass is currently being grown in the United States, Virgin Islands, China, and other areas. Disclaimer
VIASPACE, Inc. Company Blog
VIASPACE, Inc. News:
VIASPACE Chairman Interviews With WallStreetReporter and Provides Commentary
VIASPACE Giant King™ Grass Featured in Front-Page Story in St. Croix Newspaper
Board Chairman and CEO Conduct Interview With The Green Baron Report
GlobalWise Investments, Inc. (GWIV)
The QualityStocks Daily Newsletter would like to spotlight GlobalWise Investments, Inc. (GWIV). Today, GlobalWise Investments, Inc. closed trading at $0.30, up 20.00%, on 35,200 volume with 7 trades. The stock’s average daily volume over the past 60 days is 8,213, and its 52-week low/high is $0.18/$1.87.
GlobalWise Investments, Inc. (GWIV), via wholly-owned subsidiary Intellinetics, Inc., is a leading-edge technology company focused on Enterprise Content Management (ECM) solutions for the digital age. The ECM industry continues to grow rapidly as a result of unrestricted proliferation of digital content within today's business environment. Leveraging its proprietary cloud-based computing software, GlobalWise is poised to capture a significant market share of this burgeoning industry.
GlobalWise's ECM service is delivered to customers via five unique delivery models which cover the spectrum of business needs: Cloud/Saas (Software as a Service), Hardware Vendor Integrated Service, Software Vendor Integrated Service, Premise (Client-Server), Hybrid (Premise & Cloud/Saas).This diversity gives advanced security & privacy features with an on-demand structure needed for large Tier 3 and Tier 4 businesses that are currently underserved by the market.
The Intellinetics platform defines a new industry benchmark and game-changing approach by combining advanced virtualization & automated content management with an open and service-oriented architecture using web services. The company provides strategies, tactics, and technologies used to manage paper and digital assets from capture to long-term archive, without the need for manual processes conducted by a full time employee.
GlobalWise's management boasts a combined total of over 60 years in ECM leadership and industry experience. The ECM industry is expected to exceed $5.1 billion by 2013 with Gartner predicting a compound annual growth rate of 9.5%. IBM Market Insights predicts adoption of cloud computing to grow by 26% CAGR between 2010 through 2013. Leveraging management and key department heads, Intellinetics has a strong foundation from which to capture significant market share within the lucrative $149 billion Business Software & Services industry. Disclaimer
GlobalWise Investments Company Blog
GlobalWise Investments News:
GlobalWise Reports Third Quarter 2012 Financial Results and Provides Revised Fiscal 2012 Guidance
GlobalWise Teams Up With MWA Intelligence to Participate in Two Imaging Channel Conferences
GlobalWise Announces New Channel Partnership With Level Seven
VistaGen Therapeutics, Inc. (VSTA)
The QualityStocks Daily Newsletter would like to spotlight VistaGen Therapeutics, Inc. (VSTA). Today, VistaGen Therapeutics, Inc. closed trading at $0.713, up 9.69%, on 1,700 volume with 2 trades. The stock’s average daily volume over the past 60 days is 1,353, and its 52-week low/high is $0.06/$3.15.
VistaGen Therapeutics, Inc. (VSTA) is a biotechnology company applying stem cell technology for drug rescue and cell therapy. Drug rescue combines human stem cell technology with modern medicinal chemistry to generate new chemical variants ("drug rescue variants") of once-promising drug candidates that have been discontinued during late-stage preclinical development due to heart or liver safety concerns. VistaGen also focuses on cell therapy, or regenerative medicine, which includes repairing, replacing or restoring damaged tissues or organs.
VistaGen's versatile stem cell technology platform, Human Clinical Trials in a Test Tube™, has been developed to provide clinically relevant predictions of potential heart and liver toxicity of promising new drug candidates long before they are ever tested on humans.
By more closely approximating human biology than conventional animal studies and other nonclinical techniques and technologies currently used in drug development, VistaGen's human stem cell-based bioassay systems can improve the predictability of the drug development cycle and lower the cost of new drug research and development by identifying product failures earlier in the cost curve. According to the Food and Drug Administration even only a ten percent improvement in predicting failure before clinical trials could save $100 million in development costs, which savings ultimately could be passed on to patients.
Using mature human heart cells produced from stem cells, VistaGen has developed and internally validated CardioSafe 3D™, a novel three-dimensional (3D) bioassay system for predicting the in vivo cardiac effects of new drug candidates before they are tested in humans. VistaGen is now focused on using CardioSafe 3D™ to generate up to two new, safer small molecule drug rescue variants every twelve to eighteen months. VistaGen anticipates that these drug rescue variants will be modified versions of once-promising new drug candidates that have been discontinued by pharmaceutical companies and academic research institutions because of heart toxicity concerns, despite substantial prior investment and positive efficacy data demonstrating their potential therapeutic and commercial benefits. In most cases, VistaGen plans to license or sell its new, safer drug rescue variants in strategic partnering arrangements with global pharmaceutical companies, arrangements providing VistaGen with both near term and downstream milestone payments and economic participation rights but without future development cost obligations.
VistaGen's lead drug candidate, AV-101, is in Phase Ib development in the U.S. for treatment of neuropathic pain, a serious and chronic condition causing pain after an injury or disease of the peripheral or central nervous system.
Neuropathic pain affects approximately 1.8 million people in the U.S. alone. Although the current active AV-101 IND is for the treatment of neuropathic pain, VistaGen's development plan and regulatory strategy for AV-101 has been designed to allow its Phase 1 safety studies to support Phase 2 development for depression, epilepsy, Huntington's Disease and Parkinson's disease, indications for which there is now supporting preclinical efficacy data. To date, VistaGen has been awarded over $8.5 million from the U.S. National Institutes of Health (NIH) for development of AV-101.
VistaGen is also developing LiverSafe 3D™, a novel predictive liver toxicity and drug metabolism bioassay system for drug rescue applications. In parallel with drug rescue activities, the Company is funding early-stage nonclinical studies focused on potential cell therapy applications of its Human Clinical Trials in a Test Tube™ platform. Disclaimer
VistaGen Therapeutics, Inc. Company Blog
VistaGen Therapeutics, Inc. News:
VistaGen Therapeutics Becomes Member of Centre for Commercialization of Regenerative Medicine Consortium
VistaGen Therapeutics Enhances Predictive Liver Toxicology and Drug Metabolism Bioassay System -- LiverSafe 3D™
VistaGen Therapeutics and Duke University Announce Heart Tissue Engineering Progress at American Heart Association 2012 Scientific Sessions
TNI BioTech, Inc. (TNIB)
The QualityStocks Daily Newsletter would like to spotlight TNI BioTech, Inc. (TNIB). Today, TNI BioTech, Inc. closed trading at $9.20, up 0.11%, on 9,184 volume with 21 trades. The stock’s average daily volume over the past 60 days is 47,231, and its 52-week low/high is $0.72/$10.01.
TNI BioTech, Inc. (TNIB) is focused on utilizing patented immunotherapy to activate and mobilize the body's immune system to combat fatal diseases. The company's products and technologies improve the treatment and diagnosis of cancer, infections such as HIV/AIDS, and autoimmune diseases. Future initiatives include treatment for multiple sclerosis, herpes viral infections, and other conditions that result in altered-immune response.
The company's product portfolio currently includes IRT-101, an active immunotherapy that works by activating a patient's immune system against infectious diseases and tumor cells; IRT-102, an adaptive immunotherapy that works by isolating and enriching a patient's own immune cells; and IRT-103, an active immunotherapy that works by activating a patient's immune system against HIV/AIDS and tumor cells.
Leveraging the advantages of today's cutting-edge treatment options, the company aims to meet the growing demand for quality healthcare with safer, more effective radiation therapy; new-targeted drug therapies; and minimally invasive surgical alternatives around the world. TNI BioTech most recently signed a letter of intent to open clinics in Africa that will provide advanced treatment for cancer, HIV/AIDS, and autoimmune diseases.
The company plans to continue clinical trials in China during 2012 and 2013, and anticipates starting trials in the United States by early 2013.The company is also in negotiations to acquire a number of other immunotherapy products, patents, and therapies. Led by a management team with decades of experience and solid business plan, TNI BioTech is poised to improve healthcare with active and adaptive forms of improved immunotherapies. Disclaimer
TNI BioTech, Inc. Company Blog
TNI BioTech, Inc. News:
TNI BioTech, Inc. Signs Exclusive Distributor Agreement for Federal Republic of Nigeria with G-Ex Technologies/St. Maris Pharma & GB Pharma Holdings LLC
TNI BioTech Inc., and Hubei Qianjiang Pharmaceuticals Co., Ltd., Announce Venture Partnership for the Development of New Drug for Cancer Therapies
Dr. Henry "Skip" Lenz, Pharm.D, Joins TNI BioTech, Inc., as Quality Control Officer
Today before the opening bell, VIASPACE announced its Board Chairman, Dr. Kevin Schewe, participated in a detailed interview with Juan Costello of the WallStreetReporter last week. The conversation reviews the recent corporate developments at VIASPACE and how the company is positioning itself to capitalize on opportunities in the promising bioenergy sector. The full interview can be heard using the following link: www.wallstreetreporter.com/viaspace.
“This was a new investor audience to VIASPACE and I spent the first half of the interview reviewing our history and then detailing all our recent news announcements since the first of October,” stated Dr. Schewe regarding the interview. “However, the last two questions gave me an opportunity to provide an interesting overview of our status and outlook.”
The following is a transcript of the last two questions.
Question: What is your viewpoint on the opportunities and challenges in the sector, and how are you positioning your company to capitalize?
Answer: The opportunities are enormous and quite literally global in scope. For example, we are currently engaged in the various stages of new business deals in eight different countries around the world. We have done an excellent job of increasing the global awareness of Giant King Grass as the highest yielding, dedicated energy crop in the world. We are not randomly pounding on doors; new customers are now calling us and requesting to meet with us, many of them are actually anxious to get started with Giant King Grass projects and we get involved in helping them with their due diligence as step number one.
For more information on VIASPACE, visit www.VIASPACE.com
Viscount Systems has been in the security technology business since 1969, with their products installed all over the world in corporate, institutional, and residential environments. Today, it’s more than just a matter of public safety. With vast amounts of critical information now reducible to the size of a standard thumb drive, the demand for security and access control is paramount. Viscount continues to grow its technology, establishing easier and more efficient ways to monitor and coordinate security efforts, regardless of how numerous and wide spread they may be.
In 2003, Viscount introduced a comprehensive security software system called MESH, with applications for telephone entry, card access, building directories, alarm, and video, with the system’s capabilities continuing to expand as new versions are released. The newest add-on module for MESH is called Facility Friend, designed to facilitate the management of staff and visitors through manned entrances. Applications include photo badging, visitor management, incident reporting, scheduling, banned visitors, and lost and found.
Facility Friend is a web based application allowing unlimited numbers of corporate locations to be linked for comprehensive facility management, including photo badging and visitor management. The system includes support for a number of ID scanners for simplified enrollment and tracking. Individualized passwords allow users to pre-register visitors. The system also allows management to add a range of user defined database fields to track vehicles, packages, lost and found, incident reporting, and banned visitor lists.
Another addition is ABC Vault, a Cloud-based software application for disaster recovery and contingency planning. The software effectively creates an enterprise-wide database and relational drawings of every piece of life safety related electronics, including door locations, in every facility managed by an agency or corporation. It enables users to create drawings of any door object in a facility and permanently store all drawings of all facilities. Users can add notes to define the make and model of each device, installation dates, and so forth. It also allows users to download and store any facility documents that may be required for disaster recovery. This includes fire alarm, HVAC, IT, plumbing, or any other building schematics/drawings.
For more information, visit www.viscount.com
In October of 2012, Cardium Therapeutics, a health sciences and regenerative medicine company focused on the acquisition and strategic development of innovative health products, acquired To Go Brands, a developer of easy-to-use nutraceuticals. To Go Brands products are known for being 100% natural, organic, and antioxidant rich, but in convenient forms that can be used in the home or on the run, such as drink mixes and capsule-based dietary supplements.
The acquisition was a natural one for Cardium, representing with its dynamic brands an important portal to the wide-ranging health community. To Go Brands, through its developing Web presence and social networking, is increasingly positioning itself as an information source as well as a product source. The company uses Facebook, Twitter, Pinterest, and other social media to actively connect with the rapidly growing market of people seeking the healthy lifestyle.
An example is the company’s ongoing use of unique and fun health-oriented recipes that represent a natural draw to health conscious consumers. Examples include Sweet and Simple Apple Oatmeal, Green & Icy! Non-dairy Ice Cream, Pacific Northwest Smoothie, Key Lime Delight, Healthy To Go Breakfast, Super Fruit ‘n Flax Smoothie, and various creative drinks.
A recent sampling of the To Go Brands blog covers everything healthy:
• Holiday Weight Loss Guide
• Candy to Avoid
• Why Whey Protein
• Green Coffee Bean- The New Magic Bean
• Losing weight naturally!
• Omega To Go® eliminates the “Middle Fish”
• What is ACAI?
• 7 Important Nutrients and How They Benefit the Body
• Is Stress Causing Your Weight Gain?
For additional information, visit www.CardiumTHX.com and www.ToGoBrands.com
Heavy Earth Resources has assembled a significant position in some of the most exciting hydrocarbon targets Colombia and Guatemala have to offer. The company is continuing to pursue an acquisitive strategy focused on diligent identification of strong petroleum geology fundamentals in proven production areas, as well as under-explored targets showing equivalent commercial promise.
HEVI holds a 50% interest in a large (some 57.3k acres) exploration and production contract in the prolific Llanos basin (~1.5B bbls total documented recovery potential), including the exceptional Morichito block, via their Colombia-focused subsidiary, DCX SAS, who is busily managing the company’s interests in the country from their HQ in Bogota. Morichito is sandwiched between four producing fields, including two 20k bopd producers (CEPSA’s Caracara field and Hocol, S.A.’s Guarrojo block). This play also takes advantage of the Bicentennial Pipeline (Morichito block to Coveñas) construction, in combination with the expansion of production/storage infrastructure in Cartagena.
Latest word has it that HEVI is ready to enter the first stage of their current drilling/development program for the Morichito block and the company has retained noted industry veteran (and recent Board appointee), B.A. (Brian) Hepp, to take the COO position. Production was slated to commence on the Morichito-5 discovery well in the October report (as the company had acquired all necessary accoutrements to start commercial production on the Morichito-5), with drilling on the Morichito-5B sidetrack well also beginning. HEVI looks to be on-target for their projected Q1 2013 production milestone and the latest report on the company’s net share of prospective resources at Morichito (P10 calculation with customary discount at 0 and 10% before deduction of income tax) indicates a value on the 37.42M bbls somewhere in the range of $1.079B to $585M (P50 calc on 7.89M bbls using the same application yields a range of roughly $128M to $80.1M). HEVI was also able to capture a huge database of 3D seismic data on the Morichito (some 58 square miles worth), opening up even more potential production targets and reinforcing the rich resource model for the site already envisioned by the HEVI team.
Another 25% interest via DCX SAS in a similar exploration and production contract (here some 27.7k acres, acquired in mid-May) in the Lower Magdalena basin, is also surrounded by serious production (Cicuco, Boquete, and La Creciente Fields). Easy drilling characteristics in the geology, which is largely porous/highly-permeable shallow water sandstone/limestone, makes the (late 2009-drilled) Noelia-1 exploration well an easy node to develop from at the La Maye block and HEVI has three other prospects already identified here for drilling.
On HEVI’s Guatemalan front we have some ridiculously under-explored targets in the north (haven’t seen activity since the late 80′s) which are on-trend with and show analogous hydrocarbon geology to the prolific Xan and Chocop fields. Seven massive exploration blocks offer abundant opportunity for the company to employ their advanced 2D/3D seismic and explorative drilling capabilities, thus we should see some high-energy bid activity here before the close of the year, with awards looking more like Q1 2013.
For further information on Heavy Earth Resources, visit www.HeavyEarthResources.com
Today's Top 3
Investor News Source
Lions of Wall Street
The QualityStocks Public Company Sponsor News
- Get profiles for new featured companies at clients.qualitystocks.net
- Consorteum Holdings, Inc. (CSRH) Files Form 10-K Report With the Securities and Exchange Commission
- Cardium Therapeutics, Inc. (CXM) Announces Patent Award For Rights To Cardiovascular Gene Therapy For The Treatment Of Heart Disease
- DoMark International, Inc. (DOMK) Subsidiary and Infrared/Solar Apple Accessory Leader, SolaWerks™, Launches New Website
- The Guitammer Company Inc. (GTMM) Insiders Acquire An Aggregate Of 156,000 GTMM Shares In Open Market Purchases
- GlobalWise Investments, Inc. (GWIV) Reports Third Quarter 2012 Financial Results and Provides Revised Fiscal 2012 Guidance
- International Stem Cell Corp. (ISCO) Announces Significant Progress Towards Clinical Development
- Loans4Less.com, Inc. (LFLS) Reports Financial Results for the Third Quarter of 2012
- TNI BioTech Inc. (TNIB) Signs Exclusive Distributor Agreement for Federal Republic of Nigeria with G-Ex Technologies/St. Maris Pharma & GB Pharma Holdings LLC
- Viaspace, Inc. (VSPC) Board Chairman and CEO Conduct Interview With The Green Baron Report
- VistaGen Therapeutics, Inc. (VSTA) Enhances Predictive Liver Toxicology and Drug Metabolism Bioassay System -- LiverSafe 3D™